Targeting the PI3K/AKT Pathway: Ipatasertib Shows Promise as Maintenance Therapy for PIK3CA-Mutated, HER2-Positive Metastatic Breast Cancer
The Phase 1b SOLTI-1507 IPATHER trial demonstrates that adding the AKT inhibitor ipatasertib to trastuzumab and pertuzumab is a safe and clinically active maintenance strategy for patients with PIK3CA-mutated HER2-positive metastatic breast cancer, potentially overcoming therapeutic resistance.